Exubera inhaled insulin in patients with type 1 and type 2 diabetes: The first 12 months

Diabetes Technology and Therapeutics

Volumn 11, Issue 7, 2009, Pages 427-430

  Alabraba, Victoria ^a   Farnsworth, Adele ^a   Leigh, Rebecca ^b   Dodson, Paul ^a,b   Gough, Stephen C L ^a,b   Smyth, Theresa ^a  

^a SELLY OAK HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN ASPART; ISOPHANE INSULIN; METFORMIN; RECOMBINANT HUMAN INSULIN; REPAGLINIDE; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ARTICLE; CLINICAL ARTICLE; DIABETIC RETINOPATHY; DRUG INDICATION; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHOBIA; PRIORITY JOURNAL; RHINITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; BLOOD; DRUG EFFECT; GLUCOSE BLOOD LEVEL; INHALATIONAL DRUG ADMINISTRATION; INJECTION; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; PATIENT SATISFACTION; PSYCHOLOGICAL ASPECT; SPIROMETRY;

ADMINISTRATION, INHALATION; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FORCED EXPIRATORY VOLUME; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN; PATIENT SATISFACTION; PHOBIC DISORDERS; SPIROMETRY;

EID: 70349338648     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2008.0131     Document Type: Article

References (15)

1. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil L; The International DAWN Advisory Panel: Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-2679.
2. Rubino A, McQuay LJ, Gough SC, Kvasz M, Tennis P: Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK. Diabet Med 2007;24:1412-1418.
3. Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA: Patient satisfaction and glycaemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004;27:1318-1323.
4. Freemantle N, Blonde L, Duhot D, Hompesch M, Eggertsen R, Hobbs FD, Martinez L, Ross S, Bolinder B, Stridde E: Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005;28:427-428.
5. National Institute for Health and Clinical Excellence: final appraisal determination: inhaled insulin for the treatment of diabetes (types 1 and 2). http:==www.nice.org.uk=nice media=pdf=Inhins3-FAD.pdf (accessed April 14, 2009).
6. Munslow VJ, Smyth T, Gough S: An audit of the effectiveness of Exubera in patients with type 1 and type 2 diabetes [abstract]. Diabet Med 2008;25(Suppl 1):57.
7. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977-986.
8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.
9. Reichard P, Nilsson BY, Rosenqvist U: The effect of longterm intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329:304-309.
10. Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study. The Kroc Collaborative Study Group. JAMA 1988;260:37-41.
11. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998; 116:874-886.
12. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O: Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br Med J (Clin Res Ed) 1985;290:811-815.
13. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.
14. Quattrin T, Belanger A, Bohannon NJ, Schwartz SL: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2622-2627.
15. Skyler JS, Weinstock RS, Raskin P, Yale JF, Barrett E, Gerich JE, Gerstein HC; Inhaled Insulin Phase III Type 1 Diabetes Study Group: Use of inhaled insulin in a basal=bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 2005;28:1630-1635.